September 20 – 22, 2017 | San Diego, CA
Sheraton San Diego Marina

 

NEW ADC & IO Combo Day

 

Wednesday September 20

09.00

Chair’s Opening Remarks

        Jay Harper, Senior Scientist, MedImmune
09.10

ADC & IO Combinations 2017: Where Have we Come From & What will the Future Hold?

  •  Explore clinical landscape of combining ADCs with immuno-oncology combinations
  • Review current approaches of combining ADCs with immune checkpoint inhibitors
  • Improve understanding of the scientific rationale for combination therapy

      Jay Harper, Senior Scientist, MedImmune

Improving Understanding of Scientific Rationale for Effective Combination Therapies

09.40

Combination Approaches with Immune Checkpoint Inhibitors & Immunomodulatory Agents to Enhance Folate Receptor-α/β Targeted Chemotherapy: Learning from Animal Models

  • While immune cell infiltration varies greatly among different cancer types, folate receptortargeted small-molecule drug conjugates can modulate tumor microenvironment according to their unique mechanism of action
  • EC1456, a folate-targeted microtubule depolymerizing agent, work synergistically with anti-PD-1 antibody against a lung carcinoma model and with a standard-of-care agent against a renal cell carcinoma model
  • EC2629, a folate-targeted DNA alkylating agent with anti-FRβ+ TAM activity, can effectively treat both FRα- and FRα+ TNBC models and its effect against ovarian cancer can be further enhanced by concurrent anti-CTLA-4 treatment

           June Lu, Director, Translational Research, Endocyte

10.10

Morning Break & Networking

11.00

ADCs: Preferred Partners for Checkpoint Inhibitors

  • Overview of immunogenic cell death and the hallmark features associated with that process
  • Detail Seattle Genetics in vitro data characterizing auristatin mediated immunogenic cell death and subsequent immune activation
  • Highlight the immune activation seen in vivo with auristatin ADCs
  • Provide evidence that auristatin ADCs pair with checkpoint inhibitors to drive a robust anti-tumor response preclinically and highlight data from the 2016 ASH presentation on the BV/Nivo combination study

    Shyra Gardai, Associate Director, Seattle Genetics
11.30

Think Tank Roundtable Sessions

More practical and highly interactive breakout roundtables where attendees can crowdsource solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.
12.00

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the
findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion for information dissemination.
 12.30

Lunch & Networking

 Clinical Learnings of ADC & Immune Checkpoint Modulators Combinations

 13.30

Clinical Case Study: Clinical Learning from Mirvetuximab Soravtansine (IMGN853)  and Pembrolizumab Combination Therapy

  • Improve understanding of the synergy of combining ADC with immune checkpoint inhibitors
  • Explore the rationale for combining mirvetuximab soravtansine with pembrolizumab
  • Review most up to date clinical data

       Anna Berkenblit, Chief Medical Officer, ImmunoGen

 14.00

Afternoon Networking

The Future: Evaluating Future Development of ADC & IO Combinations

14.30

Panel Discussion: Challenges & Opportunities with ADC & IO Combos

  • Lessons learned from progress in the field so far
  • Evaluating opportunities over the next 12 months
  • How do different stakeholders need to contribute?

       Louie Naumovski, Senior Medical Director, AbbVie

 15.00

Chair’s Closing Remarks

         Jay Harper, Senior Scientist, MedImmune

17.30

Poster Session & Drinks Reception